Ability to aggregation of basic regular blood elements of patients with hypertension and dyslipidemia receiving non-medication and simvastatin

• Main Authors: Skoryatina Aleksandrovna, Zavalishina S.Yu
• Format: Article
• Language: English
• Published: DiscoverSys 2017-07-01
• Series: Bali Medical Journal
• Online Access: https://balimedicaljournal.org/index.php/bmj/article/view/553

<p><strong>Background:</strong> In this connection, we put in our work the following aim: to define the potential of simvastatin and non-medication combined impact on regular blood elements' aggregative features of patients with arterial hypertension and dyslipidemia.</p><p><strong>Methods:</strong> In our investigation, we took 55 patients of middle age with arterial hypertension of 1-2 degree, risk 3 with dyslipidemia of IIb type. For dyslipidemia correction, all the patients were prescribed simvastatin, hypolipidemic diet and graduated exercise. Registration of clinical and laboratory indices was made before the start of treatment, in 6, 12, 18, 52 and 104 weeks of therapy. We applied biochemical, hematological and statistical methods of investigation. Control group was composed of 26 healthy volunteers of the middle age examined once.</p><p><strong>Results:</strong> Application to patients of simvastatin, hypolipidemic diet and graduated exercise during 104 weeks positively influenced lipid composition and level of lipid peroxidation in plasma and regular blood elements taking the given indices on the control level for 12 weeks. Fulfilled therapy normalized in patients with arterial hypertension and dyslipidemia erythrocytes' aggregative abilities (aggregates' quantity decreased by 47,1% during 6 weeks, and ability to platelets' aggregation (aggregation inhibited with ADP on 74,1%, with collagen - on 47,1%) and neutrophils (aggregation weakened with lectin on 58,3%, with phytohemagglutinin - on 37,2% during 12 weeks.</p><p><strong>Conclusion:</strong> Simvastatin reception on the background of non-medication by patients with arterial hypertension and dyslipidemia normalizes lipid composition and level of lipid peroxidation in plasma and regular blood elements for 12 weeks of investigation. These patients' therapy lowers erythrocytes' aggregative abilities for 6 weeks, and platelets' and neutrophils' - for 12 weeks of therapy.</p><p> </p>